List of Excipients in Branded Drug OCALIVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	CELLULOSE, MICROCRYSTALLINE	2036-04-26
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	FERRIC OXIDE YELLOW	2036-04-26
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	MAGNESIUM STEARATE	2036-04-26
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	POLYETHYLENE GLYCOL 3350	2036-04-26
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	POLYVINYL ALCOHOL	2036-04-26
Intercept Pharmaceuticals Inc	OCALIVA	obeticholic acid	69516-005	SODIUM STARCH GLYCOLATE TYPE A POTATO	2036-04-26

# Ocaliva Excipient Strategy and Commercial Opportunities for Obeticholic Acid

Last updated: August 15, 2026

Ocaliva, the obeticholic acid product developed by Intercept Pharmaceuticals, uses a conventional immediate-release tablet platform with a limited excipient burden. The commercial opportunity is no longer centered on copying the marketed tablet. It is centered on improving tolerability, reducing food and hepatic-impairment risks, enabling differentiated delivery, and developing alternative bile-acid or FXR-agonist products with stronger regulatory positioning.

Ocaliva received accelerated FDA approval in 2016 for primary biliary cholangitis, or PBC, in adults with an inadequate response to ursodeoxycholic acid or as monotherapy for patients unable to tolerate it. Its nonalcoholic steatohepatitis, or NASH, indication was rejected in 2023. FDA later determined that the confirmatory evidence did not verify clinical benefit in PBC and moved to withdraw the indication in 2024. These regulatory developments materially reduce the value of an Ocaliva-specific generic strategy and increase the value of platform technologies that can be applied to next-generation FXR agonists. [1-4]

What is Ocaliva and how is the product formulated?

Ocaliva contains obeticholic acid, a semi-synthetic bile-acid analogue and farnesoid X receptor agonist. The product is supplied as 5 mg and 10 mg film-coated tablets for oral administration. [1]

What excipients are used in Ocaliva tablets?

The Ocaliva tablet core uses standard pharmaceutical excipients:

Component	Functional role
Lactose monohydrate	Diluent and tablet-mass contributor
Microcrystalline cellulose	Dry binder, diluent and compression aid
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Film-coating excipients	Color, protection, swallowability and appearance

The formulation is consistent with an immediate-release, direct-compression or low-complexity wet-granulation platform. The public label identifies the principal inactive ingredients, but does not provide a complete manufacturing formula, supplier grade, particle-size distribution or process-control strategy. Those variables can materially affect blend uniformity, dissolution and stability. [1]

What does the excipient profile indicate about Ocaliva’s formulation strategy?

The formulation prioritizes manufacturability and conventional oral delivery rather than a high-complexity solubility-enhancement system. That approach is commercially efficient, but it leaves room for differentiated products based on:

• Improved dissolution and exposure consistency.
• Reduced tablet size.
• Lactose-free or low-allergen positioning.
• Better swallowability for older PBC patients.
• Flexible dosing for patients requiring dose reduction.
• Reduced food-effect variability.
• Multiparticulate or liquid delivery for patients with dysphagia.

The key technical issue is not simply tablet compression. Obeticholic acid is a poorly water-soluble bile-acid derivative, so particle engineering, wetting, salt selection, solid-state control and dissolution testing can materially influence product performance.

What excipient strategies could improve obeticholic acid products?

A successful strategy should address clinical-use problems identified in the Ocaliva label and in the regulatory history of the product. The most credible opportunities are described below.

Can a lactose-free Ocaliva formulation create commercial value?

Yes, but lactose removal alone is unlikely to support strong differentiation. Lactose is a common tablet diluent, and replacing it with mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose or spray-dried cellulose could support a lactose-free claim.

The commercial value would be highest if the replacement also improves:

• Tablet hardness at lower compression force.
• Disintegration after aging.
• Moisture stability.
• Patient acceptability.
• Compatibility with a smaller tablet.

A lactose-free product could be useful for patients with lactose intolerance or excipient sensitivities, but the population is unlikely to justify a premium product without a second benefit.

Can solubility-enhancing excipients improve obeticholic acid exposure?

Potentially. Relevant approaches include:

Technology	Candidate excipient classes	Commercial objective
Amorphous solid dispersion	Hypromellose acetate succinate, PVP/VA, copovidone	Increase apparent solubility and dissolution
Wetting enhancement	Poloxamers, sodium lauryl sulfate at controlled levels	Improve dissolution of hydrophobic drug particles
Lipid-based delivery	Medium-chain triglycerides, surfactants, co-solvents	Increase dispersion in gastrointestinal fluids
Cyclodextrin complexation	Hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin	Improve aqueous presentation of drug
Nanocrystal formulation	Polymer stabilizers and surfactants	Increase surface area and dissolution rate
Salt or co-crystal approach	Counterion or coformer selected for solid-state performance	Improve manufacturability and dissolution

These approaches require careful evaluation because obeticholic acid acts on bile-acid pathways, and excipients that alter intestinal solubilization or absorption could change exposure in patients with hepatic impairment. A higher-exposure formulation could worsen safety risk if the original dose-response relationship is not preserved.

Is a modified-release formulation commercially attractive?

A modified-release formulation could target peak-related tolerability, dosing frequency and exposure control. Potential systems include hydrophilic matrix tablets, coated multiparticulates and gastro-resistant or delayed-release systems.

The commercial case is limited by the clinical role of Ocaliva. PBC dosing is already once daily, so reducing dosing frequency does not create a major advantage. A modified-release product would need to demonstrate a meaningful benefit, such as:

• Lower peak concentration.
• Better tolerability.
• Reduced pruritus-related discontinuation.
• More stable exposure in hepatic impairment.
• Reduced food-related variability.

A new release profile would probably require substantial comparative pharmacokinetic and clinical evidence. It could be difficult to justify for an Ocaliva follow-on product after the product’s regulatory setbacks.

What formulation patents could protect an obeticholic acid product?

Formulation protection would generally focus on the dosage form and manufacturing process rather than the active ingredient alone. Potential claim categories include:

1. Amorphous obeticholic acid with specified polymer content and crystallinity.
2. A tablet containing a defined particle-size distribution.
3. A composition with a specified dissolution profile.
4. A lipid or self-emulsifying delivery system.
5. A multiparticulate product with enteric or sustained-release coating.
6. A manufacturing process that controls polymorph, residual solvent or impurity formation.
7. A fixed-dose combination with another PBC therapy.
8. A pediatric or dysphagia-oriented liquid or dispersible formulation.

The strongest formulation claims would link composition to measurable performance, such as dissolution, bioavailability, stability or reduced pharmacokinetic variability. Broad claims covering common excipient substitutions are more vulnerable to invalidity and design-around strategies.

How strong is the Ocaliva patent estate?

The commercial strength of an Ocaliva patent estate depends on the jurisdiction, claim scope, Orange Book listing status and remaining term. Active-ingredient and use claims generally provide stronger protection than routine tablet-composition claims. Formulation claims based only on standard excipients usually have lower blocking power unless they require a specific structure, process or performance profile.

The regulatory position is more important than patent term for commercial planning. FDA’s action on the PBC indication and the failure of the NASH development program reduce the expected value of a long-lived formulation patent. A technically valid patent may still have limited economic value if the reference product has restricted market demand or if competing PBC therapies have stronger clinical positioning.

What is the FDA regulatory status of Ocaliva?

Ocaliva was approved through the accelerated-approval pathway for PBC in 2016. The label included a boxed warning concerning serious liver injury in patients with PBC and advanced cirrhosis, particularly when dosing was inappropriate for hepatic status. [1]

What FDA milestones affect Ocaliva’s commercial value?

Date	Event	Commercial effect
May 2016	FDA accelerated approval for PBC	Established the reference product
2020	FDA warning regarding serious liver injury and dosing risk	Increased prescribing and risk-management burden
May 2023	FDA issued complete response letter for NASH	Removed the largest expansion opportunity
2023-2024	FDA pursued withdrawal of the PBC indication after confirmatory concerns	Increased generic, licensing and investment risk
2024	New PBC competitors entered or approached the market	Reduced strategic value of an Ocaliva-only platform

FDA’s NASH rejection was particularly damaging because NASH had been the principal value-expansion pathway for obeticholic acid. Without that indication, commercial demand is concentrated in PBC, a substantially smaller market.

What is the Orange Book status of Ocaliva?

The Orange Book status must be assessed by product number and jurisdiction at the time of a proposed filing. Ocaliva is an NDA product, and any remaining listed patents, regulatory exclusivity and withdrawal actions must be checked against the current FDA Orange Book and FDA approval databases before filing an ANDA. [2]

A generic applicant would typically evaluate:

• Paragraph I certification if no relevant patents are listed.
• Paragraph III certification if a listed patent remains in force.
• Paragraph IV certification for an invalid, unenforceable or non-infringed patent.
• Section viii labeling strategy for method-of-use claims.
• Whether the reference product remains eligible for ANDA substitution after regulatory withdrawal or market-status changes.

The commercial value of a Paragraph IV challenge is constrained by the shrinking addressable market and the possibility that a generic would launch into a declining reference-product franchise.

What generic entry risks exist for Ocaliva?

The principal generic risks are technical and regulatory rather than purely patent-driven.

Technical risks

A generic applicant must manage:

• Obeticholic acid particle-size and polymorph differences.
• Dissolution in biorelevant media.
• Blend uniformity at 5 mg strength.
• Tablet content uniformity.
• Stability under moisture and temperature stress.
• Bioequivalence in the presence of hepatic impairment and food effects.
• Potential differences in excipient-driven absorption.

The 5 mg tablet creates a low-dose uniformity challenge. Microcrystalline cellulose and lactose can provide robust compression, but low drug loading increases segregation risk. A manufacturer may need engineered drug particles, ordered mixing or granulation to maintain content uniformity.

Regulatory risks

If FDA withdraws or changes the reference product’s approval status, the pathway for a conventional ANDA may become less predictable. A 505(b)(2) application could support a reformulated or alternative dosage form, but it would require a stronger clinical and pharmacokinetic justification.

Which companies are challenging Ocaliva commercially?

The most relevant competitive products are newer PBC therapies rather than generic obeticholic acid.

Product	Active ingredient	Company	PBC status as of 2024	Competitive position
Ocaliva	Obeticholic acid	Intercept, later acquired by Alfasigma	Accelerated approval under regulatory pressure	Established but exposed to safety and efficacy concerns
Iqirvo	Elafibranor	Ipsen	FDA approved June 2024 for PBC with inadequate response or intolerance to UDCA	Direct oral competitor
Livdelzi	Seladelpar	CymaBay, acquired by Gilead	FDA approval followed in 2024	FXR-sparing PPAR-delta approach with pruritus and biochemical-control positioning
Ursodiol	Ursodeoxycholic acid	Multiple manufacturers	Standard first-line PBC therapy	Low-cost foundation therapy

Iqirvo and Livdelzi weaken the rationale for investing heavily in a generic Ocaliva tablet unless the entrant has a low-cost manufacturing advantage, a rapid filing strategy or a formulation that solves a recognized clinical problem. [5-7]

What commercial opportunities exist for Ocaliva excipients?

The highest-value opportunities are platform-oriented.

Excipient suppliers

Suppliers can target:

• Direct-compression grades for low-dose bile-acid tablets.
• High-functionality binders that reduce tablet size.
• Superdisintegrants optimized for hydrophobic actives.
• Solubility-enhancing polymers for poorly soluble FXR agonists.
• Taste-masking systems for liquid or dispersible products.
• Low-moisture excipients for improved stability.

The strongest commercial proposition is not an Ocaliva-specific excipient. It is a formulation platform applicable to obeticholic acid, seladelpar, elafibranor and other hepatology compounds.

Contract development and manufacturing organizations

CDMOs can offer value through:

• Particle engineering.
• Amorphous solid dispersion development.
• Multiparticulate coating.
• Low-dose tablet uniformity.
• Comparative dissolution and biorelevant testing.
• 505(b)(2) formulation development.
• Scale-up of solvent- or spray-drying processes.

A CDMO with existing bile-acid handling, containment and analytical capabilities would have a stronger position than a general tablet manufacturer.

Branded reformulation opportunities

A branded reformulation would need a clear clinical or operational advantage. The most plausible concepts are:

1. A smaller lactose-free tablet.
2. A dispersible tablet for dysphagia.
3. A liquid formulation for dose titration.
4. A low-peak formulation designed to improve tolerability.
5. A combination product with a complementary PBC therapy.
6. A formulation that improves exposure consistency in patients with impaired bile flow.

The commercial hurdle is high. FDA’s safety concerns and the availability of newer therapies make a reformulated Ocaliva product difficult to position without new clinical evidence.

How does Ocaliva compare with newer PBC therapies?

Ocaliva has the advantage of earlier market entry and established clinical use. Its disadvantages include hepatotoxicity concerns, pruritus, dosing complexity in hepatic impairment and the collapse of the NASH expansion thesis.

Newer therapies may support stronger commercial economics because they can be positioned around improved tolerability, pruritus control, or different mechanisms. Excipient development should therefore focus on transferable formulation capabilities rather than a single-product Ocaliva investment.

Key Takeaways

• Ocaliva uses a conventional immediate-release film-coated tablet with lactose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate as principal core excipients.
• The strongest formulation opportunities are solubility enhancement, lactose-free low-dose tablets, dysphagia-friendly delivery and controlled exposure.
• Lactose substitution alone is unlikely to justify a premium product.
• A modified-release product has limited value because Ocaliva is already dosed once daily.
• FDA’s NASH rejection and later action concerning the PBC indication substantially reduce the value of an Ocaliva-centered investment.
• Generic applicants face low-dose uniformity, dissolution, hepatic-impairment and reference-product-status risks.
• The best commercial opportunity is an excipient and manufacturing platform applicable to multiple PBC and FXR-related products.
• Iqirvo and Livdelzi increase competitive pressure and reduce the strategic attractiveness of an Ocaliva-only formulation program.

FAQs

Can Ocaliva be reformulated as a liquid?

Yes. A liquid or dispersible formulation could address dysphagia and dose flexibility, but it would require stability, palatability, preservative, dosing-accuracy and bioequivalence development.

Which excipient is most important for Ocaliva tablet performance?

Microcrystalline cellulose is likely to have a major effect on compression and tablet robustness, while sodium starch glycolate has a major effect on disintegration. Drug particle properties may be more important than either excipient for dissolution.

Would an amorphous obeticholic acid formulation be patentable?

Potentially, if the formulation has defined solid-state characteristics and demonstrates a measurable performance benefit. Claims limited to routine polymer selection would face greater validity and design-around risk.

Is a generic Ocaliva product commercially attractive after FDA’s regulatory action?

The opportunity is limited. It depends on the final regulatory status, remaining market demand, listed patents and the ability to launch at materially lower cost than newer PBC therapies.

Could the Ocaliva excipient platform be used for other bile-acid drugs?

Yes. Direct-compression excipients, particle engineering, solubility-enhancement systems and low-dose uniformity controls can be adapted to other poorly soluble bile-acid analogues and hepatology products.

References

1. U.S. Food and Drug Administration. (2023). Ocaliva (obeticholic acid) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). FDA issues complete response letter for Ocaliva in nonalcoholic steatohepatitis.
4. U.S. Food and Drug Administration. (2024). FDA proposes withdrawal of accelerated approval for Ocaliva in primary biliary cholangitis.
5. U.S. Food and Drug Administration. (2024). FDA approves Iqirvo for primary biliary cholangitis.
6. U.S. Food and Drug Administration. (2024). FDA approves Livdelzi for primary biliary cholangitis.
7. Intercept Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.